FOLH1 and prostate carcinoma: In the prospect of clinical application as an imaging biomarker for the assessment of therapy response or prognosis of OS of patients with advanced prostate cancer, it could be argued that systematic overestimation or underestimation plays a minor role as long as the estimated whole-body PSMA-TV is inherently consistent within the applied algorithms.